tiprankstipranks
Advertisement
Advertisement

PHRRF Stock Latest News

PharmaTher Files U.S. Patent to Bolster Peptide Microneedle Patch Platform
Company AnnouncementsPharmaTher Files U.S. Patent to Bolster Peptide Microneedle Patch Platform
2d ago
PharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
PremiumCompany Announcements
PharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
20d ago
PharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform
PremiumCompany Announcements
PharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform
1M ago
PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
PremiumCompany Announcements
PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
2M ago
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
PremiumCompany Announcements
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
3M ago
PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
PremiumCompany AnnouncementsPharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
3M ago
PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
Premium
Company Announcements
PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
4M ago
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
Premium
Company Announcements
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
5M ago
PharmaTher Poised for Growth as FDA Prioritizes Ketamine
PremiumCompany Announcements
PharmaTher Poised for Growth as FDA Prioritizes Ketamine
6M ago
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
PremiumCompany Announcements
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
6M ago
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
PremiumCompany Announcements
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
6M ago
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
PremiumCompany Announcements
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
6M ago
Psychedelic: Enveric announces EB-003 manufacturing milestones
PremiumThe FlyPsychedelic: Enveric announces EB-003 manufacturing milestones
6M ago
ENVB
NRXP
PharmaTher Advances Ketamine Strategy with Strategic Asset Sale
Premium
Company Announcements
PharmaTher Advances Ketamine Strategy with Strategic Asset Sale
6M ago
PharmaTher provides update on ketamine development, commercial strategy
Premium
The Fly
PharmaTher provides update on ketamine development, commercial strategy
6M ago
PharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
PremiumCompany Announcements
PharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
7M ago
PharmaTher announces sales of ketamine ANDA
PremiumThe Fly
PharmaTher announces sales of ketamine ANDA
7M ago
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
PremiumCompany Announcements
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
8M ago
PharmaTher Advances U.S. Market Strategy Following FDA Approval of KETARx™
PremiumCompany Announcements
PharmaTher Advances U.S. Market Strategy Following FDA Approval of KETARx™
8M ago
PharmaTher provides update following FDA approval of ketamine
PremiumThe FlyPharmaTher provides update following FDA approval of ketamine
8M ago
Psychedelic: atai Life Sciences, Cybin report earnings results
Premium
The Fly
Psychedelic: atai Life Sciences, Cybin report earnings results
8M ago
ATAI
CYBN
PharmaTher Receives FDA Approval for KETARx™, Paving Way for New Opportunities
Premium
Company Announcements
PharmaTher Receives FDA Approval for KETARx™, Paving Way for New Opportunities
8M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >